Venus Remedies Ltd.

327.95 +23.05 ▲7.6%

28 March 2024, 04:01:00 PM
Volume: 7,289

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.venusremedies.com
Market Cap 436.30 Cr.
Enterprise Value(EV) 410.36 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) 21.72 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) 15.03 Trailing Twelve Months Ending 2023-12
Industry PE 41.54 Trailing Twelve Months Ending 2023-12
Book Value / Share 357.47 Trailing Twelve Months Ending 2023-12
Price to Book Value 0.91 Calculated using Price: 326.40
Dividend Yield 0.00 Period Ending 2023-03
No. of Shares Subscribed 1.34 Cr. 13,366,988 Shares
FaceValue 10
About Venus Remedies Ltd.
Venus Remedies incorporated in 1989, is a pharmaceutical manufacturing company. The company provides formulations in area of anti-biotics and oncological therapeutics.

Venus Remedies Ltd. Delivery

Delivered Qty
Traded Qty

Venus Remedies Ltd. Performance

1 Day
+7.56%
1 Week
+1.69%
1 Month
-3.17%
3 Month
-17.03%
6 Month
+31.02%
1 Year
+98.16%
2 Year
+13.42%
5 Year
+910.63%
10 Year
+35.97%

Venus Remedies Ltd. Fundamental Ratios

9 years 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 1.12 0.38 -4.13 -8.18 -8.23 -3.05 17.4 9.85 5.9
Return on Capital Employed (%) 5.74 5.35 2 1.17 -0.67 0.9 12.37 7.89 7.75
Return on Assets (%) 0.62 0.2 -2.12 -4.05 -3.85 -1.45 10.3 7.18 4.5

Venus Remedies Ltd. Balance Sheet

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 457 438 389 362 333 323 400 440 460 471
Non Curr. Liab. 222 212 180 158 137 96 58 46 58 60
Curr. Liab. 163 193 197 230 264 225 97 93 83 110
Minority Int.
Equity & Liab. 841 843 765 751 733 644 556 579 601 640
Non Curr. Assets 608 566 506 491 467 350 322 301 278 267
Curr. Assets 233 277 259 260 265 294 234 278 323 374
Misc. Exp. not W/O
Total Assets 841 843 765 751 733 644 556 579 601 640

Venus Remedies Ltd. Profit and Loss

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 464 418 400 372 322 339 548 600 556 562
Other Income 1 2 4 2 6 5 20 8 10 11
Total Income 465 420 404 375 328 345 568 608 566 573
Total Expenditure -375 -337 -349 -333 -289 -299 -494 -538 -495 -497
PBIDT 90 83 55 42 39 46 73 70 71 76
Interest -41 -38 -36 -36 -25 -13 -13 0 0 0
Depreciation -46 -42 -40 -34 -34 -32 -35 -34 -32 -29
Taxation 3 -2 5 -3 1 -2 13 4 -11 -18
Exceptional Items -9 -9 23
PAT 5 2 -17 -31 -29 -10 62 41 27 29
Minority Interest
Share Associate
Other Related Items
Consolidated Net Profit 5 2 -17 -31 -29 -10 62 41 27 29
Adjusted EPS 5 1 -14 -25 -23 -8 50 30 20 22

Venus Remedies Ltd. Cash Flow

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 53 68 47 59 31 45 78 132 41 37
Cash Fr. Inv. -95 -67 3 -18 -11 -11 -5 56 -17 -51
Cash Fr. Finan. 40 -1 -46 -44 -39 -35 -73 -162 -9 -1
Net Change -2 -1 3 -4 -20 -1 0 26 15 -15
Cash & Cash Eqvt 4 4 7 4 -20 3 2 29 43 21

Venus Remedies Ltd. Shareholding Pattern

9 Qtrs 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%)
Promoter 40.81 40.81 41.76 41.76 41.76 41.76 41.76 41.76 41.76
Public 59.19 59.19 58.24 58.24 58.24 58.24 58.24 58.24 58.24
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Venus Remedies Ltd. Announcements

Sat, 23 Mar 2024
Closure of Trading Window
Closure of trading window.
Mon, 11 Mar 2024
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Venus Remedies Ltd secured Good Manufacturing Practices (GMP ) approval from UNICEF
Fri, 08 Mar 2024
Venus Remedies Receives Marketing Authorizations For Oncology Drug In Ukraine (Asia CIS).
Venus Remedies receives Marketing Authorizations for Oncology Drug in Ukraine (Asia CIS).

Venus Remedies Ltd. Technical Scans

Thu, 28 Mar 2024
Closing Above Previous High Closing Above Previous High
Close Below Last Month Low Close Below Last Month Low
High Decrease in 3 Months High Decrease in 3 Months
High Increase in 6 Months High Increase in 6 Months
High Increase in 1 Year High Increase in 1 Year

Venus Remedies Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 388,812.23 1,620.50 +0.8%
Cipla Ltd. 120,673.12 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. 102,679.14 6,171.85 +2.0%
Zydus Lifesciences Ltd. 101,151.67 1,007.35 +0.8%
Mankind Pharma Ltd. 92,029.19 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. 91,330.58 6,347.35 +1.9%
Divi's Laboratories Ltd. 91,234.91 3,452.55 +2.6%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 43.66 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-12 32.54 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 19.64 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-12 34.01 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-12 53.29 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 115.71 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-12 65.97 3,452.55 +2.6%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 6.23 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-12 4.66 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.82 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-12 5.37 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-12 10.36 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 13.52 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-12 7.00 3,452.55 +2.6%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 0.02 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,452.55 +2.6%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 12.85 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,452.55 +2.6%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 12.85 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,452.55 +2.6%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,452.55 +2.6%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,452.55 +2.6%

Venus Remedies Ltd. FAQ's

What is Venus Remedies share price?

Can I buy Venus Remedies shares now?

What is the Market Cap of Venus Remedies?

What are the key metrics to analyse Venus Remedies?

What is the 52 Week High and Low of Venus Remedies?

What is the trend of Venus Remedies share price?